REVIEW ARTICLE

Pulsatile Drug Delivery Systems: A Comprehensive Review

Ravali V[1], P Balaji[2*]

[1]School of Pharmaceutical Sciences, VISTAS, Pallavaram, Chennai, Tamil Nadu, India.
[2]Department of Pharmacology, School of Pharmaceutical Sciences, VISTAS, Pallavaram, Chennai, Tamil Nadu, India.

Received: 19th November, 2023; Revised: 12th December, 2023; Accepted: 24th February, 2024; Available Online: 25th March, 2024

ABSTRACT

A sigmoidal drug release profile is formed when a pulsatile drug delivery system (PDDI) initiates drug administration and follows it up with rapid and complete drug release. It ensures the correct dosage of the drug is delivered at the right time and place. Pulsatile drug delivery is effective for treating asthma, arthritis, cancer, diabetes, epilepsy, hypertension, ulcers, and hypercholesterolemia, among others. There are many types of delivery systems in the pharmaceutical industry, including capsular, osmotic, single and multi-unit designs and membranes that are soluble and erodible. Innovations are directed toward conditions such as those requiring nocturnal dosing, high first-pass effects, and site-specific absorption in the gastrointestinal tract. In particular, these systems make dosing more convenient for patients, resulting in better compliance. As a result of the use of chronomodulated drug delivery systems, pharmaceutical therapy is more effective with a personalized approach.

Keywords: Pulsatile drug delivery, Circadian rhythms, Chronomodulation, Chronopharmacokinetics, Disease-specific timing.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.1.65

How to cite this article: Ravali V, Balaji P. Pulsatile Drug Delivery Systems: A Comprehensive Review. International Journal of Drug Delivery Technology. 2024;14(1):463-471.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Pulsatile drug delivery systems (PDDS) were a novel and promising breakthrough in the pharmaceutical field. They were engineered to release drugs in a time-controlled, pulsatile manner, mirroring the body's inherent circadian rhythms.[1] PDDS presents a multitude of benefits, such as heightened therapeutic effectiveness, minimized side effects, enhanced patient adherence, and optimized drug pharmacokinetics.[2] This review thoroughly examines PDDS, emphasizing this innovative drug delivery approach's recent advancements, mechanisms, benefits, and challenges. Diseases can disrupt the natural biological rhythms of the human body, impacting its response to therapy. While continuous drug-release systems have been created, the evolving nature of biological systems has reduced their receptiveness to these continuous-release methods.[3] Pulsatile or chronomodulated drug release is a method in which a drug is swiftly released after a predetermined lag period. In the initial lag time, no drug is discharged from the system.[4] The resulting drug release profile takes on the form of a sigmoidal curve, which includes a phase with no drug release (lag time), succeeded by a swift and complete release of the drug, as illustrated in Figure 1. In this system, the device releases the desired drug concentration, ensuring that optimal drug levels are delivered precisely when required. This approach is particularly advantageous for drugs subject to extensive first-pass metabolism and those designed for particular segments of the intestine. It enables the attainment of a plasma peak at the most opportune moment, reducing dosing frequency and averting the development of tolerance.[5] PDDS primarily come in two forms: single-unit systems and multiparticulate systems. Multiparticulate drug delivery systems are favored over single-unit dosage forms because of numerous advantages. These include predictable gastric emptying, decreased risk of dose dumping, the flexibility to control release patterns, and enhanced bioavailability.[6] An example of multi particulate drug delivery systems is 'minitabs,' which are enclosed within a capsule. Minitabs offer the advantage of precisely controlled drug release at different points within the gastrointestinal tract. They are available in various sizes, ranging from 1.5 to 4 mm in diameter, accommodating various drug loadings. Moreover, minitabs can be further layered to modulate release rates. In conclusion, PDDS, with their capacity to synchronize drug release with the body's natural rhythms and reduce adverse effects, present a valuable approach for the treatment of diverse diseases, including those involving proteins and peptides highly susceptible to degradation.[7] Multiparticulate systems, including minitabs, hold significant promise for enhancing drug delivery within the gastrointestinal tract.

*Author for Correspondence: pharmacology.balaji@gmail.com



A. Pulsatile drug delivery system
B. conventional
C. Extended drug release

Figure 1: Graphical representation of PDDS

Advantages of PDDS[8]

Enhanced therapeutic efficacy

PDDS can optimize drug release during specific times of the day, aligning with the body's circadian rhythms. The concept of enhanced therapeutic efficacy in PDDS hinges on the ability of these systems to synchronize drug release with the body's circadian rhythms and physiological needs. This synchronization can lead to several notable advantages, ultimately resulting in significantly improved drug efficacy. It involves:

- Circadian rhythms and drug efficacy
- Precision in drug timing: reduced drug wastage
- Constant therapeutic levels
- Enhanced patient comfort and compliance
- Personalized medicine

Reduced side effects

The pulsatile release approach minimizes the exposure of the body to drugs during inactive periods, leading to a reduction in side effects and potential toxicity. This enhances patient safety and comfort during treatment. This approach offers several distinct advantages, ultimately leading to a significant reduction in side effects and potential drug toxicity, which in turn enhances patient safety and comfort during treatment. It is characterized by the following:

- Optimized drug exposure
- Minimized off-target effects
- Lower peak drug concentrations
- Minimized cumulative exposure
- Enhanced drug safety
- Improved patient comfort and compliance

Improved patient compliance

PDDS simplifies drug regimens by often requiring fewer doses throughout the day. This streamlined dosing schedule improves patient compliance, as patients are more likely to adhere to a treatment plan that is less burdensome. Patient compliance, often referred to as adherence, is a critical aspect of successful medical treatment. It describes how patients follow their prescribed treatment plans, including taking medications as directed. PDDS offer a unique advantage in enhancing patient compliance through the simplification of drug regimens.

Optimal pharmacokinetics

PDDS can finely tune drug levels to remain within the therapeutic window for extended periods, ensuring a consistently effective therapeutic outcome. This stability in drug concentration results in a better clinical response. Achieving optimal pharmacokinetics is crucial in ensuring that a drug remains within its therapeutic window, a range of concentrations where it is effective without causing significant side effects or toxicity. PDDS have the unique capability to finely tune drug levels, keeping them within the therapeutic window for extended periods. It depends upon the following:

- Therapeutic window management
- Steady-state drug levels
- Reduction of peaks and troughs
- Enhanced treatment efficacy
- Reduction of adverse effects
- Consistency in treatment

Targeted drug delivery

Targeted drug delivery is an advanced approach in pharmaceuticals where medications are delivered to specific anatomical sites or in response to physiological changes, with the aim of concentrating the therapeutic effect at the desired location while minimizing exposure to healthy tissues.[9] By incorporating stimuli-responsive mechanisms, PDDS provide an innovative and highly precise means to achieve targeted drug delivery.

Disadvantages and Challenges[9]

While PDDS offer a range of advantages, they are not without challenges and disadvantages.

Specialized expertise

Developing PDDS requires a high level of specialized expertise in various fields, including pharmaceutical science, materials engineering, and drug delivery technologies. Researchers and manufacturers need to understand the intricacies of different PDDS types, such as osmotic pumps, swellable systems, and stimuli-responsive systems, and tailor them to specific drug and disease requirements.

Materials selection

The selection of these materials must consider factors like biocompatibility, stability, and the specific drug's compatibility with the material. This material selection process adds complexity to the design and manufacturing.

Customization challenges

Customization may involve modifying the release mechanism, optimizing the dosage, and incorporating patient-specific factors. This level of individualization adds complexity to the process and requires careful consideration and testing.

Quality control and testing

It's necessary to verify that the systems release drugs as intended, maintain stability, and meet regulatory standards. This extensive testing and quality control can be time-consuming and resource-intensive.

Regulatory approval

Regulators must be convinced of the safety, efficacy, and quality of these systems, which may require substantial documentation, clinical trials, and rigorous evaluations.

Production costs

The use of advanced materials and the need for skilled personnel can further add to the production costs. These increased costs may affect the affordability and accessibility of PDDS for patients.

Lack of standardization

Unlike conventional drug delivery methods, PDDS lacks extensive standardization in terms of design and manufacturing. This variability can make comparing different PDDS and establishing consistent quality control procedures challenging.

Limited expertise

The specialized nature of PDDS may limit the number of experts in the field, making it more challenging to advance research and development.

Safety Concerns

Externally triggered PDDS represents a novel approach that relies on external factors, such as magnetic fields, temperature changes, or pH shifts, to initiate drug release. While these systems hold promise in terms of controlled drug delivery, they also raise certain safety concerns.

Unwanted Activation

Environmental factors

Externally triggered PDDS can be susceptible to environmental factors that might unintentionally activate the drug release mechanism. For example, changes in temperature, humidity, or even exposure to magnetic fields in the environment could trigger drug release when it's not intended.

Patient error

In cases where patients are responsible for activating the external trigger, there's a risk of unintentional or premature activation. Patients might inadvertently expose the system to the triggering conditions, leading to unexpected drug release.

Patient Safety and Comfort

Patient training

Patients may need to be trained on how to use and maintain externally triggered PDDS correctly. Ensuring that patients understand how to avoid unwanted activation or interference is crucial for their safety and treatment effectiveness.

Discomfort or anxiety

Patients using externally triggered systems may experience discomfort or anxiety related to their role in administering the medication. They might worry about accidentally activating the system or interfering with its function.

Limitations

While PDDS offer several advantages, they are not universally applicable to all medications or clinical scenarios. The design and use of PDDS can be restricted by various factors, limiting their scope of applicability. Let's elaborate on the reasons behind the limited applicability of PDDS:

Drug characteristics

- Drug solubility
- Chemical stability
- Narrow therapeutic index

Dosing regimen

- Frequent dosing
- Continuous therapy

Disease characteristics

- Intermittent diseases
- Steady-state therapies

Patient factors

- Patient compliance
- Age or special populations

Cost factors

The development, production, and maintenance of PDDS can be cost-intensive. High costs may limit the accessibility and affordability of such systems, making them less practical for certain patient groups or healthcare settings.

Complex manufacturing processes

The manufacturing processes for PDDS can be complex and require specialized equipment. The precision required for these systems can necessitate more advanced and expensive manufacturing techniques. Additionally, the quality control procedures for PDDS can be more rigorous, further increasing production costs.

Customization requirements

PDDS often need to be customized to suit specific drugs, their pharmacokinetics, and the targeted diseases or conditions. Customization adds to the development and manufacturing costs, as each system may require individual adjustments.

Production scale

In many cases, PDDS may not benefit from the same economies of scale as conventional drug delivery methods. The production of PDDS may be more suited to smaller-scale, specialized manufacturing facilities, which can increase production costs per unit.

Affordability and accessibility

High production costs can affect the affordability and accessibility of PDDS for patients and healthcare systems. Patients may be less likely to use PDDS if they are perceived as too expensive or if they face higher out-of-pocket costs.

Regulatory hurdles in PDDS

The regulatory approval process for PDDS can be particularly challenging due to the innovative and specialized nature of these systems. Meeting stringent safety and efficacy standards is paramount, requiring extensive testing, documentation, and a clear understanding of the unique characteristics of PDDS.

Innovative nature

PDDS represent a relatively novel approach to drug delivery, and regulatory agencies are often cautious when assessing innovative technologies. The lack of established precedents and standards specific to PDDS can make the approval process more complex.

Safety and efficacy

Regulatory agencies prioritize patient safety and treatment efficacy. For PDDS, demonstrating that the system is safe, effective, and reliable is a fundamental requirement.

Customization challenges

PDDS are often customized to suit specific drugs and diseases. This customization can add complexity to the regulatory process because each system may require individual evaluation. It's crucial to provide data demonstrating the safety and efficacy of each unique PDDS configuration.

Quality control and manufacturing

Ensuring consistent quality control and adherence to GMP was critical to regulatory approval. PDDS manufacturing must meet high standards to guarantee the reproducibility and reliability of each system.

Regulatory documentation

The regulatory submission for PDDS approval often involves substantial documentation, including detailed technical specifications, testing protocols, and data on system performance.

Clinical testing

Clinical studies are an integral part of the regulatory approval process. For PDDS, these studies must demonstrate that the system is effective and safe in real-world clinical settings.

Risk assessment

Regulatory agencies require a comprehensive risk assessment that considers potential risks associated with PDDS. This may include assessing the likelihood and severity of system failures, unintended activations, or interference.

VARIOUS TYPES OF PDDS

PDDS can be broadly categorized into time-controlled and externally triggered systems. These systems are engineered to release drugs in a pulsatile manner, either in response to specific timing or triggers



Figure: 2 Osmotic pump

Delivery Systems that Deliver Drugs on a Time-controlled Basis

Osmotic pumps

Osmotic pumps are a prominent category of time-controlled PDDS that operate based on the principles of osmosis and hydrodynamics (Figure 2). They are designed to release drugs in a controlled and consistent manner, providing a steady and precise delivery of medication over an extended period.[10]

- *Mechanism*

Osmotic pumps consist of a drug reservoir and an osmotic core, separated by a semi-permeable membrane. The drug is typically dissolved in a solution within the reservoir.

- *Drug release mechanism*

The pressure generated in the osmotic core forces the drug solution to be pushed through an orifice or a small hole in the semi-permeable membrane. The size of the orifice and the osmotic pressure inside the core are carefully engineered to control the rate of drug release. Smaller orifices and higher osmotic pressures result in slower release rates, while larger orifices and lower osmotic pressures result in faster release rates.[11]

- *Advantages of osmotic pumps*
- Precise control
- Reduced dosage frequency
- Enhanced therapeutic efficacy

- *Applications*

Osmotic pumps are commonly used for drugs with narrow therapeutic indices, meaning there is a small range between the minimum effective dose and the dose that causes adverse effects. They are also suitable for medications that need to be administered continuously over an extended period, such as pain management, cardiovascular drugs, and certain hormonal therapies.

Swellable systems

Swellable systems are a category of time-controlled PDDS designed to provide controlled and delayed release of drugs. These systems consist of a drug core encapsulated within a swellable polymer membrane. The mechanism involves the gradual swelling of the polymer membrane in response to contact with body fluids, eventually exposing the drug core for release.

- *Composition of swellable systems*

Swellable systems are typically composed of two key components:

- Drug Core: The drug to be delivered is encapsulated within the drug core, which is the central component of the system.
- Swellable Polymer Membrane**:** The drug core is surrounded by a swellable polymer membrane, which acts as a barrier.

- *Mechanism*

When the swellable system comes into contact with body fluids, the swellable polymer membrane absorbs water from the surrounding environment. As the polymer absorbs water, it gradually swells and expands, causing the polymer membrane to enlarge.

- *Applications*
- Swellable systems are particularly useful for drugs that require delayed or pulsatile release. They can be employed for various clinical scenarios where the timing of drug release is critical for therapeutic efficacy. Diseases with distinct circadian rhythms, intermittent symptoms, or specific timing requirements may benefit from swellable systems.
- *Advantages*
- Precision in timing
- Reduced dosage frequency

Time-controlled Coatings

Time-controlled coatings represent an important approach to achieving pulsatile drug release from pharmaceutical dosage forms. In this approach, coating with time-controlled polymers: Drugs are coated with specialized polymer layers that are designed to dissolve or erode at specific and predetermined rates. These polymer coatings serve as barriers, preventing the immediate release of the drug.

- *Pulsatile drug release*

The coatings dissolve or erode gradually, enabling pulsatile drug release (Figure 3). This means that the drug is released in bursts or pulses at specific time intervals rather than at a constant rate.

- *Adjustable thickness and composition*

The timing and extent of drug release can be controlled by adjusting the thickness and composition of the polymer coatings. Different polymers or combinations of polymers can be used to achieve the desired release profile.

Externally Triggered PDDS

Temperature-responsive systems

These systems are externally triggered pulsatile drug delivery systems. They rely on polymers that exhibit changes in their properties, specifically solubility, in response to variations in temperature.

- *Temperature-responsive polymers*

These systems employ lower critical solution temperature (LCST) polymers. The LCST represents the temperature at which the polymer undergoes a phase transition, shifting from a hydrophilic (water-attracting) state to a hydrophobic (water-repelling) state.

- *Drug encapsulation*

Below the LCST, the polymer remains in its hydrophilic state, and the drug is effectively encapsulated within the polymer matrix. This encapsulation prevents drug release.

- *Temperature-induced solubility change*

As the temperature surpasses the LCST, the polymer experiences a shift to its hydrophobic state, rendering it more soluble in the surrounding environment.

- *Pulsatile drug release*

The increased solubility of the polymer allows the drug to be released from the polymer matrix. This sudden change in the polymer's solubility triggers a burst or pulse of drug release, leading to a pulsatile drug delivery pattern.

pH-responsive PDDS

It are another type of externally triggered pulsatile drug delivery system. They rely on polymers that respond to changes in pH (acidity or alkalinity) to achieve controlled drug release.[12]

- *pH-responsive polymers*

These systems utilize polymers that are sensitive to pH variations. These polymers can change their structure or solubility in response to changes in the pH of their surrounding environment.

- *Encapsulation within pH-sensitive polymer*

The drug is encapsulated within a pH- sensitive polymer that is designed to respond to specific pH conditions. This polymer can be tailored to dissolve or swell within a particular pH range.

- *pH-dependent release*

When the pH of the surrounding environment matches the pH range to which the polymer is responsive, the polymer undergoes a change in its structure, solubility, or both. This change allows the drug to be released from the polymer matrix.[13]

Mechanical force-responsive PDDS

This are a category of externally triggered PDDS. They release drugs in response to mechanical forces at the target site, such as pressure or stretching.

- *Microcapsules or mechanically sensitive components*

These systems often involve using microcapsules or other mechanically sensitive components containing the drug.

- *Mechanical force application*

When mechanical forces are applied to the drug delivery system, such as pressure or stretching, these forces act on the microcapsules or components.



Figure 3: Pulsatile-based system along with the erodible coating

- *Rupture or activation*

In response to the applied mechanical force, the microcapsules may rupture, or the mechanically sensitive components may be activated. This results in the release of the encapsulated drug.

- *Pulsatile drug release*

The release of the drug is sudden and typically occurs as a burst or pulse, providing a pulsatile drug delivery pattern.[14]

Magnetic or electric field-responsive systems

Magnetic or electric field-responsive PDDS are a category of externally triggered PDDS. They utilize the presence of magnetic or electric fields to trigger drug release from systems that contain magnetic or electrically responsive components.

- *Magnetic or electrically responsive components*

These systems incorporate magnetic or electrically responsive components as part of the drug delivery system. For example, they may use magnetic nanoparticles or materials with electrically responsive properties.

External magnetic or electric field

To trigger drug release, an external magnetic or electric field is applied to the target area of the drug delivery system.

- *Response to the field*

In the presence of the external field, the system's magnetic or electrically responsive components undergo changes. For example, magnetic nanoparticles may physically disrupt the drug carrier or the drug-containing matrix.

- *Drug release*

The changes induced by the external field lead to the release of the drug. This release can be sudden and pulsatile, occurring precisely where the field is applied.

Enzyme-responsive systems

Enzyme-responsive PDDS are designed to release drugs in response to the presence of specific enzymes at a particular site within the body.

- *Incorporation of enzyme-responsive components*

These drug delivery systems incorporate components sensitive to specific enzyme activity. These components may include enzyme-responsive polymers or substrates.

- *Enzyme recognition*

The system is designed to recognize and interact with particular enzymes that are present at the target site. These enzymes could be naturally occurring within the body or associated with certain medical conditions or diseases.

- *Enzyme-triggered cleavage*

When the specific enzymes interact with the enzyme-responsive components, they trigger a cleavage or breakdown of these components. This enzymatic activity liberates the drug from its encapsulated or inactive form.

Pulsincap drug delivery system

The pulsincap drug delivery system is a specific type of pulsatile drug delivery system designed to release drugs in a pulsatile or time-controlled manner, often with a specific lag time before drug release (Figure 4). This system is particularly useful for drugs that need to be administered at precise times and in specific quantities to maximize their therapeutic effectiveness and minimize side effects.[15]



Figure 4: Pulsinap drug delivery system

- *Pulsincap design*

The Pulsincap system typically consists of a hard gelatin capsule with a drug reservoir and a plug. The capsule is filled with the drug formulation, and a hydrogel plug seals the drug reservoir.[16]

- *Delayed drug release*

The key feature of the Pulsincap system is its ability to delay drug release for a specific period, often to match the circadian rhythms or other physiological factors of the body. The hydrogel plug prevents immediate drug release upon ingestion.

- *Lag time*

During the initial phase, there is no drug release, which is known as the "lag time." This lag time is a crucial aspect of pulsatile drug delivery and can be customized based on the specific requirements of the drug and the condition it's intended to treat.

- *Trigger mechanism*

After the lag time, the hydrogel plug starts to absorb moisture from the surrounding environment, leading to swelling. Once the plug swells to a certain extent, it eventually bursts, releasing the drug from the capsule.

- *Release of drug*

The drug is released abruptly, leading to a rapid and complete release. This pulsatile release profile ensures that the drug reaches its target site precisely when needed, providing optimal therapeutic effects.

Pulsincap systems are particularly valuable for diseases that exhibit chronopharmacological behavior, where the timing of drug administration is critical for efficacy. The Pulsincap

drug delivery system offers several advantages, including improved patient compliance, reduced dosing frequency, and enhanced therapeutic outcomes.[17,18]

Various Formulation Techniques

Formulating a pulsatile drug delivery system involves several methods and approaches to achieve the desired drug release profile. These methods are used to design systems that release a drug with a specific timing or pulsatile pattern.

Coating techniques

- *Solvent casting*

This method involves dissolving or dispersing the drug in a polymer solution, which is then cast onto a core tablet or pellet. The polymer forms a coating that controls drug release.

- *Compression coating*

In this technique, drug layers are compressed with polymer layers to form a multilayer tablet. The compression coat can be designed to release the drug with a lag time.

- *Pan coating*

Used for multi-particulate systems, drug pellets or granules are coated with a pulsatile release polymer in a pan coater.

Osmotic systems

- *Osmotic pump tablets*

These tablets consist of a drug core surrounded by a semi-permeable membrane and an orifice. As water enters the tablet, pressure builds, forcing the drug out through the orifice.

- *Push-pull osmotic systems*

These systems have two osmotic chambers: one for drug release and one for pushing the drug out. This creates a delayed or pulsatile release.

Microencapsulation

- *Microencapsulation techniques*

Microencapsulation involves encapsulating drugs within tiny polymer capsules or microspheres. The drug is released when the microcapsules degrade or rupture.

Implantable devices

- *Implantable pulsatile systems*

These systems are surgically implanted and use mechanical or osmotic forces to release the drug at specified intervals.

Multiparticulate systems

Minitabs are small multiparticulate tablets that can be filled into capsules or taken as-is. They are designed to release the drug at specific points along the gastrointestinal tract.

EVALUATION STUDIES

The evaluation of PDDS is a crucial step in the development of these systems to ensure they function as intended and meet the desired therapeutic objectives. The evaluation process involves a series of *in-vitro* and *in-vivo* tests and assessments to validate the performance and effectiveness of the PDDS.

***In-vitro* Evaluation**

Drug release kinetics

The evaluation typically begins with studying the drug release kinetics of the PDDS. *In-vitro* release studies are performed under controlled conditions, such as in a dissolution apparatus, to understand the release profile of the drug. The release profile should match the desired pulsatile pattern.

Mechanical properties

The mechanical properties of the drug carrier or components are assessed for mechanically responsive systems. This involves evaluating the responsiveness of the system to the specific triggering mechanism, such as pressure, stretching, or magnetic or electric fields.

Physical stability

The physical stability of the PDDS is tested to ensure that it can maintain its structural integrity during storage and use. This includes assessments of physical parameters like size, shape, and surface characteristics.

Chemical compatibility

The compatibility of the drug with the polymer or matrix materials is examined to ensure that it remains stable and active within the system. Any potential drug-polymer interactions or degradation should be identified.

In-vitro release under stimulus

If the PDDS is designed for external stimuli-triggered release, such as temperature or pH changes, the system's response to these stimuli is assessed *in-vitro*. For instance, if it's a temperature-responsive system, the drug's release behavior at different temperatures is studied.

Enzyme-tesponsive behaviour

In the case of enzyme-responsive systems, the interaction between the system and the specific enzyme is evaluated *in-vitro* to ensure it results in the desired enzymatic cleavage and drug release.[19]

***In-vivo* Evaluation**

Pharmacokinetics

In-vivo studies involve administering the PDDS to animals or human subjects to assess its pharmacokinetics. This includes measuring plasma drug concentrations over time to determine how well the system achieves the desired pulsatile drug release in the body.

Therapeutic efficacy

The primary goal of PDDS is to improve therapeutic outcomes. Therefore, the *in-vivo* evaluation includes assessing the therapeutic efficacy of the system in animal models or patients. This may involve evaluating how well the PDDS controls disease progression and minimizes side effects.

Safety and biocompatibility

Safety assessments are conducted to determine the biocompatibility of the PDDS. This includes evaluating any

potential adverse effects, tissue compatibility, and local or systemic toxicity.

Tissue distribution

To ensure the targeted drug delivery, the distribution of the drug within the body is examined. This helps confirm that the drug is released at the intended site.[20]

Compliance and patient acceptance

In clinical studies, patient compliance and acceptance of the PDDS are assessed. Patient feedback, convenience, and adherence to the dosing schedule play a significant role in the evaluation.[21]

Long-term stability

The long-term stability and shelf life of the PDDS are also assessed to ensure that it remains effective and safe throughout its intended storage period.

Cost-effectiveness

The cost-effectiveness of the PDDS is evaluated, considering factors like production costs, ease of manufacturing, and market pricing.

FUTURE RECOMMENDATIONS AND PROSPECTS

Advanced Drug Development

Research and development in PDDS should continue to explore new materials, mechanisms, and designs to optimize drug release profiles. This can lead to further advancements in achieving the desired drug concentrations at precise times.

Tailored therapies

Future PDDS should aim to personalize drug regimens, considering individual patient factors and disease characteristics. Customized therapies could be a game-changer, particularly in complex, chronic conditions.

Multi-drug delivery

PDDS can potentially be used for delivering multiple drugs with different release profiles in a single system. This innovation can improve the management of polypharmacy and drug interactions.

Combination with targeted delivery

Integrating PDDS with targeted drug delivery systems, such as those responsive to specific tissues or cells, can enhance treatment effectiveness and minimize side effects.

Biotechnology advancements

PDDS are particularly suitable for the delivery of bio-pharmaceuticals like proteins and peptides. As biotechnology continues to grow, so will the opportunities for PDDS in this domain.

CONCLUSION

In conclusion, PDDS represents an exciting frontier in healthcare, offering innovative solutions to long-standing challenges in drug administration. By increasing therapeutic precision, enhancing patient compliance, and addressing complex disease patterns, PDDS have the potential to significantly improve patient outcomes and quality of life. With continued research and development, collaboration, and regulatory support, PDDS are poised to play a vital role in the future of medicine, offering new hope for patients and healthcare providers alike.

REFERENCES

1. Patel Vipul P, Soniwala Moinuddin M. Pulsatile Drug Delivery System for Treatment of Various Inflammatory Disorders-A Review. International Journal of Drug Development & Research, 2012; 4(3):67-87.
2. Sharma Ritika, Singh Arjun, Kumar Sunil, Jamil Faraz. Pulsatile drug delivery system. International Research Journal of Pharmacy, 2012; 3(7):103-107.
3. Amidon GL, Leesman GD. Pulsatile Drug Delivery System. US Patent No 5, 1993; 229,131.
4. Sirisha VNL, Namrata M, Sruthi B, Harika I, Kiran kumar P, Kiran Y, Kumar Rao K.Pranavi. Pulsatile Drug Delivery System-A Review. International Journal of Pharmaceutical Research & Allied Sciences, 2012; 1(3): 13-23.
5. Sachin Survase and Neeraj Kumar. Pulsatile drug delivery: Current scenario. CRIPS, 2007; 2:27-33.
6. Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: Current perspectives. J Control Release, 2009;4(134):74–80.
7. Matta Nalini Krishna reddy, Suresh bandari, Jaswanth A. Design and *in-vitro* characterization of ketoprofen core in cup pulsatile tablets for chronomodulated drug therapy. Indo American journal of pharmaceutical research, 2017;7(3): 8059-67.
8. Pradip Karale. Pros and cons of pulsatile drug delivery system. Int. J.Pharm Drug Anal, 2015;3 (8):255-260
9. Sinha VR, Bhinge JR, rachna kumria, Manoj kumar. Development of pulsatile systems for targeted drug delivery of Celecoxib for prophylaxis of colorectal cancer, 2006;13(3):221-5.
10. Balaban SM, Pike JB, Smith JP, Baile CA.Osmotically Driven Del Devices with Pulsatile Effect. US Patent No. 5209746; 1993
11. Tubati Vaniprasanna, Gopala Krishnamurthy T E, Sambasiva Ra A. An overview of chronotherapeutic drug delivery systems based on floating pulsatile concept. journal of advances in medical and pharmaceutical sciences, 2016;7(3):1-18.
12. Mohamad A, Dashevsky A. pH-independent pulsatile drug delivery system based on hard gelatin capsules and coated with aqueous dispersion Aquacoat ECD. Eur J Pharm Biopharm, 2006;64:173-9.
13. Hetal patel, Sonia Pandey, Vihari Patel, Ritesh Shah, Sanjay Twari. Pulsatile release of ketoprofen from compression coated tablets using Eudragit polymers; International journal of pharmacy and pharmaceutical sciences, 2016;8(2):224-9.
14. Manish Kumar guptha, Swarnalatha saraf. Formulation and evaluation of pulsatile drug delivery system of ramipril for controlling morning spate of B.P.; Journal of pharmaceutical research, 2018;17(1): 1-8.
15. Vijaya madhavi A, Rama brahma reddy D, Venugopal M, Srihari N, Chenniah, Koteswarao P. Formulation and evaluation of pulsatile drug delivery system of zafirlukast, Journal of drug delivery and therapeutics, 2020;10(2):122-8.
16. Bussemer T, dashevsky A, Bodmeier R. A pulsatile drug delivery system based on pulsatile coated hard gelatin capsules; Journal

of controlled release, 2003;331-39.
17. Patel VR and Patel VP: Pulsatile Drug Delivery System-A Review. Int J Pharm Sci Res, 2015; 6(9): 3676-88.
18. Modasiya Moin K. And Patel Vishnu M.: Pulsatile Drug Delivery System for Colon – A Review. International Journal of Research in Pharmaceutical and Biomedical Sciences, 2011; 2(3): 934-941.
19. Krgel I, Bodmeier R. Evaluation of an enzyme containing capsular shaped pulsatile drug delivery system. Pharm Res, 1999;16(9):1424-29.
20. Manjula B, Divyasri V, Shravya Ch, Maniteja yadav, Soujanya Ch. Formulation and evaluation of pulsatile drug delivery system of lisinopril; journal of drug delivery and therapeutics, 2019; 9(2):76-82.
21. Vishal V, Bilaskar, Indrajeet S Patil, Omkar A patil, Girishchandra R Mandke, Shrinivas K Mohite. Design, development and optimization of pulsatile drug delivery of antihypertensive drug; international research journal of pharmaceutical and biosciences, 2018; 4(6):1-18.